ReportWire

Tag: BioSpace

  • Lexaria’s Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science – Medical Marijuana Program Connection

    Lexaria’s Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science – Medical Marijuana Program Connection

    DehydraTECH-CBD now featured in eight published, peer-reviewed papers

    KELOWNA, BC / ACCESSWIRE / June 22, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that its groundbreaking research utilizing DehydraTECH-processed cannabidiol (“DehydraTECH-CBD”) has now been published in eight peer-reviewed articles in six different publications.

    The most recent paper entitled, “Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study” was published in June, 2023 in the peer-reviewed International Journal of Molecular Sciences.

    “We’re proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria. “Lexaria is establishing itself as one of the world’s leaders in the investigation of cannabidiol for the purposes of controlling human blood pressure and we are now focused on launching a FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.”

    This recent publication builds on the growing body of peer reviewed literature developed on Lexaria’s leading research into the effects of DehydraTECH-CBD upon human health, including hypertension. Additional publications on these findings include the following:

    Original Author Link click here to read complete story..

    MMP News Author

    Source link

  • Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers – Medical Marijuana Program Connection

    Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers – Medical Marijuana Program Connection

    DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility

    KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from last year’s human clinical study HYPER-H21-4 (“the Study”) demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (“CVD”) and a host of other conditions.

    After five weeks of treatment with the patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation, blood-plasma levels of interleukin (“IL”) 8, 10, and 18 were reduced by ~19%, ~27%, and ~43%, respectively. Those persons receiving five weeks of placebo experienced no significant changes in their IL levels as shown with the black bars in the graph below. The differences evidenced relative to baseline and/or placebo with pro-inflammatory biomarkers IL 8, 10 and 18 were statistically significant (p<0.05).

    Blood Plasma Levels (pg/mL) of Pro-Inflammatory Biomarkers IL-8, IL-10 and IL-18

    Lexaria Bioscience Corp., Tuesday, May 23, 2023, Press release picture

    *Solid bars are at baseline and hollow bars are at end of five weeks of treatment

     

     

     

     

    “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” said Dr. Philip Ainslie, Cardiovascular Advisor to Lexaria and Lead Investigator of…

    Original Author Link click here to read complete story..

    MMP News Author

    Source link